Monoclonal antibodies in the treatment of myelogenous leukemias

摘要: Monoclonal antibodies (mAb) differ dramatically from conventional therapeutic agents in their mechanisms of actions and biochemical biological properties [1–3]. On the one hand, mAbs are capable selective targeting tumor cells while avoiding normal tissues. MAbs able to kill via a variety intrinsic (immunological) extrinsic (by use carried cytotoxic agents) modes. other these molecules large, poorly diffusible into areas bulky disease, highly immunogenic, rendering repeated infusions difficult. These advantages disadvantages must be carefully considered application mAb treatment hematopoietic cancers.